ISSN: 1859 - 2872
Characteristics of co-occurring gene mutation in non-small cell lung cancer patient
Main Article Content
Keywords
Abstract
Objective: The aim of the study is to identify co-occurring gene alterations in patients with non-small cell lung cancer treated at Military Hospital 103. Subject and method: A prospective, cross-sectional descriptive study was conducted on 155 patients with non-small cell lung cancer who were treated at Military Hospital 103 from January 2023 to January 2025. Genomic alterations were analyzed from FFPE tissue samples using next-generation sequencing. Result: Next-generation sequencing identified gene alterations in 108 of 155 patients (69.7%). Co-occurring mutations were detected in 42.6% of patients, including 37 patients (34.3%) with two mutations and 9 patients (8.3%) with three or more mutations. EGFR mutations frequently occurred as co mutations (56.9%). The most common combination was EGFR plus BRAF in 9 patients, followed by compound EGFR mutations in 8 patients, and EGFR plus TP53 in 3 patients. Conclusion: Co-occurring gene alterations were identified in 42.6% of patients with non-small cell lung cancer, including 34.3% with two mutations and 8.3% with three or more mutations, particularly among those harboring common EGFR variants, including exon 19 deletions and exon 21 L858R.
Article Details
References
2. Keogh Rachel J, Barr Martin P, Keogh Anna et al (2024) Genomic Landscape of NSCLC in the Republic of Ireland. JTO Clinical and Research Reports, 5(2).
3. Soo Ross A, Reungwetwattana Thanyanan, Perroud Herman Andres et al (2024) Prevalence of Mutations in Patients With Resected Stages I to III NSCLC: Results From the EARLY-EGFR Study. Journal of Thoracic Oncology 19(10): 1449-1459.
4. Hondelink Liesbeth M, Ernst Sophie M, Atmodimedjo Peggy et al (2023) Prevalence, clinical and molecular characteristics of early stage EGFR-mutated lung cancer in a real-life West-European cohort: Implications for adjuvant therapy. European Journal of Cancer 181: 53-61.
5. Dang AH, Tran VU, Tran TT et al (2020) Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population. Sci Rep 10(1): 2707.
6. Lan B, Zhao N, Du K et al (2022) Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis. Oncol Lett 24(5): 384.
7. Pretelli G, Spagnolo CC, Ciappina G et al (2023) Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need. Int J Mol Sci, 24(10).
8. Peng P, Lv G, Hu J, Wang K, Lv J, Guo G (2021) Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients. Ann Transl Med 9(16): 1321.
9. Leonetti A, Sharma S, Minari R et al (2019) Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer, 121(9): 725-737.
10. Stockhammer P, Grant Michael, Wurtz A et al (2023) Co-occurring Alterations in Multiple Tumor Suppressor Genes are Associated with Worse Outcomes in Patients with EGFR-mutant Lung Cancer. Journal of thoracic oncology.
11. Yang Xiaodan, Zhong Jia, Yu Zhuo et al (2021) Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations. BMC Cancer, 21(1): 1107.
Article Sidebar
